Advanced Filters
noise
Found 393 clinical trials
K Kasra Kolahdouzan, M.D.

Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer

Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the …

18 - 85 years of age Female Phase 2

Intra-lesional Tumor Boost for Bulky Cervical Cancer

The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are: Does the extra radiation boost effectively reduce the …

19 - 80 years of age Female Phase 2
H He Hai Xin

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.

18 - 75 years of age Female Phase 2
S Site Public Contact

Detecting HPV DNA in Anal and Cervical Cancers

This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood …

18 years of age All Phase N/A
D Dan Ou

Toripalimab Combined With Definitive CCRT for LACC Patients

Cervical cancer constitutes a significant health burden for women globally. While most patients with early-stage disease can be cured with radical surgery or chemoradiotherapy, patients with high-risk locally advanced disease or with recurrent/metastatic disease have a poor prognosis with standard treatments. Immunotherapies are a rational treatment for this HPV-driven cancer …

18 years of age Female Phase N/A

Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer

Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with pathologically diagnosed stage IIB or above locally advanced cervical cancer. Under the limitations of radiotherapy and surgery conditions in …

18 - 70 years of age Female Phase 2

Implementation of Surgical Safety and Intraoperative Metastasis Identification Through Deep Learning: Multicentric Video Collection for Minimally Invasive Sentinel Lymph Node Dissection in Uterine Malignancies

The loco-regional metastatic or non-metastatic status of lymph nodes (LN) is critical for the therapeutic management of most cancer patients. Indeed, the presence or absence of lymphatic metastasis is essential for the accurate staging of the disease and strongly influence the prognosis and adjuvant treatment regimens. An important revolution in …

18 - 99 years of age Female Phase N/A
Q Qinglei Gao, MD. PhD

The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies

Recombinant oncolytic adenovirus injection (KD01)is an oncolytic vius product. Its main component is a conditionally replicativerecombinant human type 5 adenovirus, where part of the E3 region has been replaced with the gene encoding the tBid apoptoticprotein.AK104 is a humanized bispecific antibody co-targeting PD-1 (Programmed Cell Death Protein 1) and CTLA-4 …

18 years of age Female Phase 1
M Matthew Kovak, MS

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.

18 years of age All Phase 2

Study of ZG005 in Combination With Paclitaxel+Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.

18 - 70 years of age Female Phase 1/2

Simplify language using AI